These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34695137)

  • 1. Expression profile of tumour suppressor protein p53 and its regulator MDM2 in a cohort of breast cancer patients in a Tertiary Hospital in Ghana.
    Opoku F; Bedu-Addo K; Titiloye NA; Atta Manu E; Ameh-Mensah C; Duduyemi BM
    PLoS One; 2021; 16(10):e0258543. PubMed ID: 34695137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcellular localization of Mdm2 expression and prognosis of breast cancer.
    Park HS; Park JM; Park S; Cho J; Kim SI; Park BW
    Int J Clin Oncol; 2014 Oct; 19(5):842-51. PubMed ID: 24292333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
    Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
    Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression.
    Schmitz KJ; Grabellus F; Callies R; Wohlschlaeger J; Otterbach F; Kimmig R; Levkau B; Schmid KW; Baba HA
    Virchows Arch; 2006 Jan; 448(1):16-23. PubMed ID: 16208531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
    Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
    Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
    Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
    Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulation of p53-MDM2 auto-regulatory pathway in breast carcinoma.
    Baliou E; Nonni A; Keramopoulos D; Ragos V; Tsiambas E; Patsouris E; Pavlakis K
    J BUON; 2016; 21(5):1099-1103. PubMed ID: 27837610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
    Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
    Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
    J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer.
    Pinto AE; André S; Laranjeira C; Soares J
    Pathology; 2005 Feb; 37(1):45-50. PubMed ID: 15875733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.
    Shokouh TZ; Ezatollah A; Barand P
    Medicine (Baltimore); 2015 Aug; 94(32):e1359. PubMed ID: 26266392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 expression and relationship with MDM2 amplification in breast carcinomas.
    Buyukpinarbasili N; Gucin Z; Ersoy YE; İlbak A; Kadioglu H; Muslumanoglu M
    Ann Diagn Pathol; 2016 Apr; 21():29-34. PubMed ID: 27040927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
    Swetzig WM; Wang J; Das GM
    Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
    Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
    J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Analysis of bcl-2 in Association with p53 and Ki-67 in Triple Negative Breast Cancer and Other Molecular Subtypes in Ghana.
    Ameh-Mensah C; Duduyemi BM; Bedu-Addo K; Atta Manu E; Opoku F; Titiloye N
    J Oncol; 2021; 2021():7054134. PubMed ID: 34188682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.
    King SI; Purdie CA; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Meek DW
    Breast Cancer Res; 2012 Mar; 14(2):R40. PubMed ID: 22405092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
    Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
    Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer.
    Mitrović O; Čokić V; Đikić D; Budeč M; Vignjević S; Subotički T; Gulan M; Radović S; Furtula S
    Target Oncol; 2014 Dec; 9(4):367-79. PubMed ID: 24272208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical Expression Of Matrix Metalloproteinase-1 (MMP-1) in Different Types Of Breast Carcinoma And Its Comparison With ER/PER and HER2/neu.
    Shamsi FB; Anwar A; Lail RA; Bukhari MH; Naseem N; Nagi AH
    J Ayub Med Coll Abbottabad; 2022; 34(1):12-16. PubMed ID: 35466619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.